MMR vaccine

(redirected from Measles-mumps-rubella vaccine)
Also found in: Dictionary.
Related to Measles-mumps-rubella vaccine: Varicella vaccine, Polio vaccine

MMR vaccine

(ĕm′ĕm-är′)
n.
A combination of live measles, mumps, and rubella vaccine, administered subcutaneously to immunize children against measles, mumps, and rubella infections.

MMR vaccine

A trivalent vaccine containing an aqueous suspension of live attenuated strains of measles, mumps and rubella viruses grown in chick or duck embryo cells.
MMR vaccine is supplied in a lyophilised form for reconstitution before administration.

MMR vaccine

Live measles-mumps-rubella vaccine A trivalent vaccine containing an aqueous suspension of live attenuated strains of measles, mumps, and rubella viruses grown in chick or duck embryo cells. See Killed vaccine, Live attenuated vaccine.

MMR vac·cine

Abbreviation for measles, mumps, and rubella vaccine.

Patient discussion about MMR vaccine

Q. Do you know about Autism and Vaccinations? Dr. Andrew Wakefield, a famous doctor for children at the Royal Free Hospital in London made in 1998 following report...

A. this is not true!!!! as you can check in this quote from the Cochrane library:
"Measles, mumps and rubella are three very dangerous infectious diseases which cause a heavy disease, disability and death burden in the developing world. Researchers from the Cochrane Vaccines Field reviewed 139 studies conducted to assess the effects of the live attenuated combined vaccine to prevent measles, mumps and rubella (MMR) in children. MMR protects children against infections of the upper airways but very rarely may cause a benign form of bleeding under the skin and milder forms of measles, mumps and rubella. NO CREDIBLE EVIDENCE of an involvement of MMR with either autism or Crohn's disease was found. No field studies of the vaccine's effectiveness were found but the impact of mass immunisation on the elimination of the diseases has been demonstrated worldwide."

More discussions about MMR vaccine
References in periodicals archive ?
the purpose of the procurement is to find providers for the purchase of a live measles-mumps-rubella vaccine, For the active immunization of children and adults (from the age of 1) in a single dose pre-filled syringe (with a needle).
(Eds.), Immunization safety review: Measles-mumps-rubella vaccine and autism.
People are considered immune to measles if they are at least 1 year old and have received two doses of the measles vaccine, usually part of the measles-mumps-rubella vaccine; if they have already had measles, confirmed by a health professional; if they had a blood test confirming they are immune; or if they were born before 1957 and have had at least one dose of measles vaccine.
"We have a very high measles-mumps-rubella vaccine coverage level, and the vaccine effectiveness of the two-dose schedule probably prevented thousands and thousands of cases."
All health care workers should receive two doses of the measles-mumps-rubella vaccine if they don't have evidence of immunity, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention voted during a special meeting held by telephone in response to the current multistate mumps outbreak that had its beginning in Iowa late last year.
It also established a causal relation between measles vaccine and death from measles infection; oral polio vaccine and death from polio infection; and measles-mumps-rubella vaccine and anaphylaxis and thrombocytopenia, which can result in severe bruising or prolonged bleeding.
According to Clark County Public Health, as of December 2018, 78 percent of Clark County young people ages 6 to 18 had received the recommended two doses of measles-mumps-rubella vaccine, while 81 percent of very young children ages 1 to 5 had received one dose of the vaccine.
Endemic transmission of rubella was eliminated in the United States in 2004 as a result of high levels of coverage with measles-mumps-rubella vaccine (MMR) (1).
In this context, Public Health France has evaluated the vaccination activities for the first months of 2018 and notes: an increase in vaccine coverage of +5.6% for the recommended meningococcal C vaccine dose at 12 months, from 56.8% to 62.4% in one year; an increase in vaccination coverage of + 2.6% for the first dose of measles-mumps-rubella vaccine recommended at 12 months, from 72.41% to 75.0% 2.